Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants

Journal of Pathology

Volumn 232, Issue 1, 2014, Pages 16-22

  Ardighieri, Laura ^a   Zeppernick, Felix ^a,b   Hannibal, Charlotte G ^c   Vang, Russell ^a   Cope, Leslie ^a   Junge, Jette ^d   Kjaer, Susanne K ^c,e   Kurman, Robert J ^a   Shih, Ie Ming ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ovarian low grade serous carcinoma; ovarian neoplasms; serous borderline tumour

Indexed keywords

ADVANCED CANCER; ARTICLE; BRAF GENE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVARIAN SEROUS BORDERLINE TUMOR; OVARY ATYPICAL PROLIFERATIVE SEROUS TUMOR; OVARY TUMOR; PERITONEUM; PRIORITY JOURNAL;

OVARIAN LOW-GRADE SEROUS CARCINOMA; OVARIAN NEOPLASMS; SEROUS BORDERLINE TUMOUR;

CYSTADENOCARCINOMA, SEROUS; DENMARK; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MUTATION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84890045201     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4293     Document Type: Article

References (19)

1. Mayr D, Hirschmann A, Lohrs U, et al., KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883-887.
2. Sieben NL, Kolkman-Uljee SM, Flanagan AM, et al., Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am J Pathol 2003; 162: 1095-1101.
3. Sieben NL, Roemen GM, Oosting J, et al., Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J Pathol 2006; 210: 405-411.
4. Verbruggen MB, Sieben NL, Roemen GM, et al., v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior. Int J Gynecol Cancer 2009; 19: 1560-1563.
5. Krishnamurti U, Sasatomi E, Swalsky PA, et al., Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol 2005; 24: 56-61.
6. Emerson RE, Wang M, Liu F, et al., Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol 2007; 26: 387-394.
7. Diebold J, Seemuller F, Lohrs U,. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest 2003; 83: 251-258.
8. Capper D, Preusser M, Habel A, et al., Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-19.
9. Long GV, Wilmott JS, Capper D, et al., Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013; 37: 61-65.
10. Bosmuller H, Fischer A, Pham DL, et al., Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2013; 44: 329-335.
11. Jones S, Wang TL, Kurman RJ, et al., Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2012; 226: 413-420.
12. Boyd J, Luo B, Peri S, et al., Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol 2013; 130: 560-564.
13. Singer G, Oldt R, 3rd, Cohen Y, et al., Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486.
14. Alvarez AA, Moore WF, Robboy SJ, et al., K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary. Gynecol Oncol 2001; 80: 201-206.
15. Tang X, Shigematsu H, Bekele BN, et al., EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005; 65: 7568-7572.
16. Li M, Cannizzaro LA,. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum Pathol 1999; 30: 1197-1200.
17. Kurman RJ, Vang R, Junge J, et al., Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011; 35: 1605-1614.
18. Lu KH, Bell DA, Welch WR, et al., Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998; 58: 2328-2330.
19. Gu J, Roth LM, Younger C, et al., Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001; 93: 1147-1152.